Potential Lawsuit: FDA Warns of Adverse Event with Intraocular Injections of Triamcinolone, Moxifloxacin, and Vancomycin

Washington, DC: The US Food and Drug Administration (FDA) has issued information on an adverse event report concerning a patient who was diagnosed postoperatively with bilateral hemorrhagic occlusive retinal vasculitis (HORV) resulting from injections of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation. The patient developed HORV after being given injections in each eye at the end of cataract surgery procedures that were done two weeks apart. [Original Article]